Intec Pharma (NTEC) Receives Consensus Rating of “Buy” from Brokerages

Shares of Intec Pharma (NASDAQ:NTEC) have been given an average rating of “Buy” by the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.40.

Several research analysts have commented on NTEC shares. Oppenheimer set a $15.00 price target on shares of Intec Pharma and gave the company a “buy” rating in a report on Sunday, September 30th. Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a report on Wednesday, October 17th. Roth Capital started coverage on shares of Intec Pharma in a report on Friday, October 5th. They issued a “buy” rating and a $8.50 price target for the company. Finally, HC Wainwright set a $16.00 price target on shares of Intec Pharma and gave the company a “buy” rating in a report on Wednesday, October 24th.

Shares of NASDAQ:NTEC opened at $5.92 on Friday. Intec Pharma has a one year low of $3.55 and a one year high of $8.55. The firm has a market capitalization of $196.96 million, a price-to-earnings ratio of -3.59 and a beta of 1.00.

Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings results on Wednesday, August 15th. The biotechnology company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.02). On average, equities research analysts anticipate that Intec Pharma will post -1.36 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Acuta Capital Partners LLC raised its position in shares of Intec Pharma by 8.7% during the 2nd quarter. Acuta Capital Partners LLC now owns 2,962,568 shares of the biotechnology company’s stock valued at $13,035,000 after buying an additional 238,285 shares in the last quarter. Prosight Management LP purchased a new position in Intec Pharma in the 2nd quarter worth $4,951,000. 683 Capital Management LLC purchased a new position in Intec Pharma in the 2nd quarter worth $660,000. DAFNA Capital Management LLC purchased a new position in Intec Pharma in the 2nd quarter worth $2,502,000. Finally, Jane Street Group LLC purchased a new position in Intec Pharma in the 1st quarter worth $185,000. Hedge funds and other institutional investors own 45.09% of the company’s stock.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: Penny Stocks, Risk and Reward Factors

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply